Secura Bio, Inc.
$442.6K 382 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Emergent BioSolutions Inc.
Emergent BioSolutions Inc. reported $442,152.99 across General Payments, Research, and Ownership to 4 physicians and teaching hospitals across 28 transactions.
- $442.2K
- All-tracks total
- 28
- Transactions
- 4
- Recipients
- −$185.0K
- General Payments vs PY2023
Emergent BioSolutions Inc. reported $442,152.99 across all CMS Open Payments tracks (General + Research + Ownership) to 4 physicians and teaching hospitals in Program Year 2024 - ranking #793 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $6,831.98, averaging $110.5K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer emergent-biosolutions-inc Emergent BioSolutions Inc.
$442.2K · #793/1,925 · 0.0% industry · PY2024
- TOT $442.2K
- RANK #793
- SHARE 0.0%
- TXN 28
- RCP 4
- CAT 3
- GEN $6.8K
- ΔGEN −$185.0K
- TOP1 35.1%
- PY 2024
Volume peers
Nearest volume peer: Secura Bio, Inc. ($442.6K)
Emergent BioSolutions Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Emergent BioSolutions Inc.'s CMS-reported General Payments decreased by $185.0K (−96.4%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: EMERGENT BIOSOLUTIONS INC.PY2023: EMERGENT BIOSOLUTIONS INC.PY2024: Emergent BioSolutions Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $191,851.17
- PY2024
- $6,831.98
What the Data Shows for Emergent BioSolutions Inc.
$442,152.99: that is what Emergent BioSolutions Inc. reported in payments to 4 physicians and teaching hospitals during Program Year 2024, spread across 28 transactions ($15.8K per transaction, $110.5K per recipient). The company sits at rank #793 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
"Compensation for Services Other Than Consulting" leads the 3-category general-payment breakdown below at $4.4K (64.4% of General Payments, 2 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 3 types of general payments, Emergent BioSolutions Inc.'s largest category was "Compensation for Services Other Than Consulting" at $4.4K - 64.4% of General Payments.
How Emergent BioSolutions Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $4.4K | 2 | 64.4% |
| Consulting Fee | $2.3K | 1 | 33.3% |
| Food and Beverage | $156.98 | 1 | 2.3% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $6,831.98 (100.0%) of $6,831.98 in this company's General Payments records across 4 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Emergent BioSolutions Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Marc Katz
$2,400.00 across 1 reported transactions
- 2
David Kleinman
$2,275.00 across 1 reported transactions
- 3
Marjorie Driese
$2,000.00 across 1 reported transactions
- 4
Robert Peter Kadlec
$156.98 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Emergent BioSolutions Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Emergent BioSolutions Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Emergent BioSolutions Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Asahi Intecc USA, Inc.
$443.1K 1,313 recipients
Compare payment profiles
Magenta Medical Inc
$440.4K 39 recipients
Compare payment profiles
RedDress LTD
$439.2K 0 recipients
Compare payment profiles
BSN Medical Inc
$445.4K 328 recipients
Compare payment profiles
Caption Health, Inc.
$438.6K 2 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.